PMPRB Summary of VCUs & Orders - 2003

Click on medicine to view details of VCU

DATE OF APPROVAL MEDICINE PATENTEE %Above Guidelines PRICE REDUCTION1 EXCESS REVENUES2 PAYMENTS PATENT STATUS
VCUs
October 21, 2003 Dostinex Pfizer Canada Inc. $42,116.31 $42,116.31 Expired 11/2000
April 26, 2003 Aromasin Pharmacia Canada Inc. 15.6 - 5.5 See VCU for details $87,484.65 By price reduction
March 31, 2003 Remicade12 Schering Canada Inc. Yes - by 20% $7,792,650.89 $7,792,650.89
ORDER

1.There are no price reductions in cases where the PMPRB's jurisdiction ceased with the expiry or the dedication (prior to 1995) of the patent.

2. In all cases, all excess revenues were offset through further price reduction and/or payment.

12. Notice of Hearing issued on December 16, 2002.

Date modified: